CLYM CLYM
Company Profile ↓Company Overview
CLYM (CLYM) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +633.53% |
| 6 Months: | +142.14% |
| 3 Months: | +8.91% |
| 1 Month: | -7.08% |
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)50.04 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | -1.61M | -2.26M | -6.88M | -8.71M | -9.38M | -13.13M | -13.70M | -8.75M | -23.44M | -6.71M | -5.00M | -3.00M | -56.37M | -11.73M | -23.02M | -10.68M | -14.89M | -15.21M |
| Net Income | -1.63M | -2.26M | -18.60M | -8.72M | -9.62M | -13.20M | -14.60M | -9.68M | -22.29M | -5.22M | -3.97M | -1.70M | -54.89M | -8.89M | -20.78M | -8.67M | -12.89M | -13.72M |
| Diluted EPS | - | - | - | -3.11 | -0.70 | -0.50 | -0.37 | -0.37 | -0.84 | -0.19 | -0.15 | -0.06 | -1.81 | -0.13 | -0.31 | -0.13 | -0.19 | -0.20 |
| R&D Expense | 1.32M | 1.93M | 4.27M | 5.48M | 5.99M | 8.26M | 8.77M | 4.26M | 5.72M | 3.69M | 2.88M | 1.09M | 1.05M | 6.24M | 17.33M | 6.58M | 9.07M | 9.37M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Income | -20.93M | -35.67M | -45.13M | -40.27M | -82.02M | -67.88M |
| Net Income | -20.67M | -47.48M | -45.24M | -35.12M | -73.90M | -59.85M |
| Diluted EPS | - | -4.24 | -1.72 | -1.30 | -1.53 | -0.88 |
| R&D Expense | 8.77M | 23.32M | 26.21M | 15.41M | 14.34M | 46.71M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 24.63M | 173.24M | 134.99M | 110.47M | 217.19M | 167.74M |
| Total Equity | -5.56M | -24.98M | 167.20M | 128.72M | 107.60M | 211.88M | 160.47M |
| Cash & Equivalents | - | 20.49M | 46.92M | 43.59M | 93.11M | 87.23M | 35.69M |
| Total Liabilities | - | 3.06M | 6.04M | 6.28M | 2.87M | 5.31M | 7.27M |
| Current Liabilities | - | 3.06M | 6.03M | 6.10M | 2.83M | 4.93M | 6.98M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -14.10M | -36.07M | -37.37M | -20.60M | -15.56M | -54.36M |
| Investing Cash Flow | 8.08M | -114.97M | 34.44M | 68.98M | -121.09M | 2.83M |
| Financing Cash Flow | 4.92M | 177.23M | 0 | 841.00K | 130.73M | -21.00K |
| Capital Expenditure | - | - | - | - | -0 | -186.00K |
| Free Cash Flow | - | - | - | - | -15.56M | -54.54M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - |
| ROE % | 82.7% | -28.4% | -35.2% | -32.6% | -34.9% | -37.3% |
| ROCE % | -97.0% | -21.3% | -35.0% | -37.4% | -38.6% | -42.2% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CLYM
FDA Fast Track and a BTIG Buy; Is Climb Bio (CLYM) a Must-Buy Small Cap Stock? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxNRjM2Q0dRX0twRHF4d2dtVXVac3dTOFRzQ0ZSWjVRaEQ0SGM1SmxfZmZ0U3hyMjkzcmhsc3ZZbkpzc2tYbTBLNEI3MGVnZmlMc1doV1hLOWhFS1R5ZWV6Sm9hWktramtfZndBOV9ObWdzWDdSSFhVM012Rko1SWtzS1FGQzdDdkNQaElvVV…
$CLYM stock is down 12% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxNRVRFdU1DXzBITDdaRF82OHowX3g2N2MyWDFNbDd1TjJNYWRkaWEwRHFKeS1Ydm1IVnNxY0YtNTc0b1NCM01HSmhQcjVVVERwczNDUDJzMjc4TFhXczdOSEEzdHlKSUI4Y2NKZE1oMnhHY1U5c21WcEt3VlM0NklwSk5GMHB6WDQzUDZwX1…
Piper Sandler Maintains Climb Bio(CLYM.US) With Buy Rating, Maintains Target Price $23 - Moomoo
<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxONTlqWmNjNzFLX0p4OGF1MEhVbk1YUUJkc2RDNkdrSGd6dnp3WFh6RTJvRllKTjFldzl3NFNReDBQQ2xiS3NIRFZoUUYwYVJ1Z05kWU9Rb3BYejZydThjZHlmeEZvX1AydkxjVUhjOE93YnBHOGNqZF9DZE56d2VhQTdwZUQ2WUQ0c1N1N0…
Climb Bio, Inc. Actuals & Estimates (NASDAQ:CLYM) - TradingView
<a href="https://news.google.com/rss/articles/CBMihgFBVV95cUxOaXhhNnd2ZlNJMXhsNGxrX29ZYS0wcEZvSVpCZ3pxdDVKUlVucFlRSlhoWXROQ2FuUm94UElXbE0wRDZHMUQ4VW9VZEhGYVNkNnJSdU11OS1kczYyZVdCZm83SFpUV2l2UUZKbWxaazZlbXJIRGRwbS00NkxpYWRKSk1tUW8tdw?oc=5" t…
Climb Bio Stock Pre-Market (+6.4%): Wedbush Initiates at Outperform, $12 Target - Trefis
<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxNTkwxSEpKT0JlM29uU2J1clRCOWVKM1E4cnJfNVhMNHdQVjBWQ0YwSm01SDhqSXBlakQ3REJRV1RHRklrTWc3cmdVVndLRUJsVTMzMTF5Y3lDSTdKdzhxSmN4SE5mX3FIWksyeE1uNjRQdGNyeHpPT1ZJNU4zM0tRLWM5dGNyVXRSOEdkRz…
Climb Bio’s May 5 webcast maps budoprutug’s path in 3 diseases - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxOWGdOdXNWdDIzcnpJU0x6cElQcTFTU0o1Vk9mXy1ueWF5R3E0OUZyODJMQ2Z2NEN3d2NBd3A5WjFVN2UwYlMwYWJVT2RSckRab0dhaFZodFFjbmRLcUxDMjUxNUdicmp2cXlRT1lQc3k5ZVBVaEtyeXlHNDM5Q2lya3Jyd3RsemYxRUxVbG…
CLYM — Frequently Asked Questions
What is the current share price of CLYM?
As of 2026-08-05 17:25 PDT, CLYM trades at $12.47 on NASDAQ/NYSE. Its 52-week range is $1.61 to $14.00.
What is the P/E ratio of CLYM?
CLYM trades at a trailing price-to-earnings (P/E) ratio of -14.17.
What is the return on equity (ROE) of CLYM?
CLYM has a return on equity (ROE) of -37.30%. Its return on capital employed (ROCE) is -42.23%.
Is CLYM a good stock to buy?
This page provides a data-driven analysis of CLYM, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.